Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Trocio

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Vaccine|March 10, 2005
DermaVir, a novel HIV immunisation technologyFranco Lori, Jeffrey Trocio, Nyasha Bakare, et al.
Journal of Managed Care & Specialty Pharmacy|September 25, 2015
Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United StatesAlpesh Amin, Amanda Bruno, Jeffrey Trocio, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 22, 2015
Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United StatesAlpesh Amin, Amanda Bruno, Jeffrey Trocio, et al.
Journal of Medical Economics|January 15, 2015
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the USAlpesh Amin, Amanda Bruno, Jeffrey Trocio, et al.
BMC Urology|May 24, 2011
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree modelSalvador Arlandis-Guzman, Carlos Errando-Smet, Jeffrey Trocio, et al.
Journal of Thrombosis and Thrombolysis|December 16, 2014
Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial resultsAlpesh Amin, Yonghua Jing, Jeffrey Trocio, et al.
Journal of Medical Economics|August 1, 2014
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patientsAlpesh Amin, Yonghua Jing, Jeffrey Trocio, et al.
American Health & Drug Benefits|May 4, 2017
Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care EstimatorThanh-Nghia Nguyen, Jeffrey Trocio, Stacey Kowal, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 28, 2018
Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settingsJeffrey Trocio, Virginia M Rosen, Anu Gupta, et al.
Hospital Practice (1995)|July 28, 2015
Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarinAmanda M Farr, Yonghua Jing, Stephen Johnston, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Vaccine|March 10, 2005
DermaVir, a novel HIV immunisation technologyFranco Lori, Jeffrey Trocio, Nyasha Bakare, et al.
Journal of Managed Care & Specialty Pharmacy|September 25, 2015
Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United StatesAlpesh Amin, Amanda Bruno, Jeffrey Trocio, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|May 22, 2015
Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United StatesAlpesh Amin, Amanda Bruno, Jeffrey Trocio, et al.
Journal of Medical Economics|January 15, 2015
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the USAlpesh Amin, Amanda Bruno, Jeffrey Trocio, et al.
BMC Urology|May 24, 2011
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree modelSalvador Arlandis-Guzman, Carlos Errando-Smet, Jeffrey Trocio, et al.
Journal of Thrombosis and Thrombolysis|December 16, 2014
Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial resultsAlpesh Amin, Yonghua Jing, Jeffrey Trocio, et al.
Journal of Medical Economics|August 1, 2014
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patientsAlpesh Amin, Yonghua Jing, Jeffrey Trocio, et al.
American Health & Drug Benefits|May 4, 2017
Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care EstimatorThanh-Nghia Nguyen, Jeffrey Trocio, Stacey Kowal, et al.
Clinicoeconomics and Outcomes Research : CEOR|December 28, 2018
Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settingsJeffrey Trocio, Virginia M Rosen, Anu Gupta, et al.
Hospital Practice (1995)|July 28, 2015
Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarinAmanda M Farr, Yonghua Jing, Stephen Johnston, et al.
Pageof 4